What Is Zymeworks Inc. (ZYME) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Zymeworks Inc.'s intrinsic value is estimated at $9.67, suggesting the stock is overvalued at its current price of $24.66. With 10 out of 12 models flagging downside (-60.8% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at +6.6% (fair value: $26.29), while ML-RIV is the most conservative at -95.6% ($1.08). The spread between these extremes — +102.2% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About ZYME?
12 of 13 models are currently active for ZYME. Of these, 1 model suggests upside while 11 models suggest overvaluation. The Bayesian DCF estimates ZYME's intrinsic value at $6.48, implying -73.7% downside from the current price. See which stocks rank higher →
How Does ZYME Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, ZYME ranks #56 by Quality of Company score. CirclFi's QOC score of 7.3/10 evaluates 32 fundamental signals. A score of 7.3 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Zymeworks Inc. operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating ZYME should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ZYME a Value Trap?
The Value Trap algorithm is not active for ZYME. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Zymeworks Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Zymeworks Inc.'s fundamental quality profile registers 7.3/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +102.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ZYME valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ZYME's 12 active models, average confidence is 32%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad